The emergence of clinical enterococcal isolates resistant to both ampicillin and vancomycin is a cause of great concern, as there are few therapeutic alternatives for treatment of infections caused by such organisms. We evaluated the effects of the combination of ampicillin with vancomycin against vancomycin-resistant clinical enterococcal isolates. Using both the checkerboard technique and time-kill curves, we examined 28 strains of enterococci (17 Enterococcusfaecalis and 11 Enterococcusfaecium strains) with different levels of resistance to vancomycin. Of these, 15 strains were also highly gentamicin resistant, and 9 demonstrated resistance to ampicillin. Only seven strains of E. faecalis were inhibited synergisticaly by the combination of vancomycin with ampicilin, and even then, the concentrations of vancomycin at which synergism was demonstrated were above levels achievable in serum. None of the ampicillin-resistant isolates (all E. faecium) were inhibited synergistically at any concentration of the drugs. In no instance was bactericidal synergism observed, and in most cases the combination resulted in less killing than with ampicillin alone. Antagonism was not observed at clinically relevant concentrations. The results of this study suggest that the combination of vancomycin with ampicillin has little to offer against these emerging pathogens.
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Treatment of serious enterococcal infections is undertaken with combinations of penicillin, ampicillin, and/or vancomycin with an aminoglycoside in order to achieve bactericidal synergism. However, the presence of enterococci with high-level resistance to aminoglycosides, which in consequence are also resistant to the synergistic bactericidal actions of these combinations, is becoming a prevalent situation in many centers (4, 6) . We recently have demonstrated among clinical isolates ofEnterococcusfaecalis great variability in their susceptibility to killing by ampicillin or vancomycin as single agents, which suggests that the likelihood of successful treatment with a single agent when bactericidal therapy is required will prove strain dependent (1) . A more recent problem has been the appearance of enterococcal strains that are resistant to vancomycin, some of which are also resistant to ampicillin and penicillin (5, 10) . The emergence of such isolates is a cause of concern and leaves few therapeutic alternatives. However, it has been suggested that combinations of vancomycin with ampicillin may be synergistic against vancomycin-resistant enterococci (7, 13) . Therefore, we undertook the present study in order to evaluate the effects of the combination of ampicillin with vancomycin against vancomycin-resistant clinical enterococcal isolates. Using both the checkerboard technique and time-kill curves, we examined 28 strains of enterococci with different levels of resistance to vancomycin. Of these, 15 strains were also highly gentamicin resistant, and 9 demonstrated resistance to ampicillin. Study of combined antimicrobial activity. Inhibitory activities of ampicillin and vancomycin in combination were studied by the microdilution checkerboard technique. Plastic microdilution trays (Dynatech Laboratories, Inc., Alexandria, Va.) contained vancomycin in serial twofold dilutions from 2,048 to 0.2 ag/ml alone and in combination with ampicillin in serial twofold dilutions from 1,024 to 0.12 ,ug/ml. The inoculum was adjusted to approximately 106 CFU/ml, and after incubation for 24 h, the MICs of each antibiotic, alone and in combination, were noted; fractional inhibitory concentration (FIC) indexes were calculated. Syn-ANTIMICROB. AGENTS CHEMOTHER. 
RESULTS
Susceptibility tests. Nineteen strains were susceptible to ampicillin (<2 ,ug/ml), and MICs of ampicillin against the remaining 9 were .128 ,ug/ml. Twenty-five strains demonstrated high-level resistance to vancomycin (>256 ,ug/ml), and of these two were highly susceptible to teicoplanin (MICs, 0.12 and 0.5 ,ug/ml), and the remainder were inhibited by teicoplanin at concentrations of between 8 and 128 ,ug/ml. MICs of vancomycin against three strains were 8, 32, and 64 ,ug/ml, and these were all susceptible to teicoplanin at '1 ,ug/ml. Nine strains were highly resistant both to ampicillin and vancomycin.
Inhibitory activity of the ampicillin-vancomycin combinations. tion (strain 310), but that concentration was also quite high (32 ,ug/ml). None of the ampicillin-resistant isolates (all E. faecium) were inhibited synergistically at any concentration of the drugs. Antagonism was not observed at clinically relevant concentrations.
We sought a possible effect of preinduction of vancomycin resistance on synergism with one strain by inoculating a checkerboard tray from an overnight culture grown in the presence of vancomycin (10 ,ug/ml). The results were identical with those obtained with an overnight culture in antibiotic-free broth, with no evidence of synergism in either case.
Time-kill kinetic studies. Figure 1 demnonstrates the bactericidal activity of the combination of ampicillin (10 ,g/ml) and vancomycin (20 p,g/ml) against 18 ampicillin-susceptible and vancomycin-resistant strains. In no instance was bactericidal synergism observed, and in most cases the combination resulted in less killing than with ampicillin alone.
Combination of ampicillin (2 to 4x MIC, 500 iag/ml) with vancomycin (20 and 200 ,uglml) against three unique (ribotype) ampicillin-resistant and highly vancomycin-resistant strains yielded no evidence of bactericidal activity or synergistic interaction (data not shown). In no case was antagonism between ampicillin and vancomycin noted.
DISCUSSION
Resistance of enterococci to vancomycin precludes useful synergism between this antimicrobial agent and aminoglycosides which require inhibitory activity of the cell wall-active drug (7, 11 alone, but the clinical significance of the differences observed is not obvious. The increasing emergence of strains of enterococci with concomitant resistance to the antibiotics used as standard therapies for serious enterococcal infections, as well as the absence of synergistic activity with combinations of these antimicrobial agents, is disquieting. The results of this study suggest that the combination of vancomycin with ampicillin has little to offer against these emerging nosocomial pathogens.
